Protalix (PLX) Director Pol F. Boudes Receives 25,500-Share Award

What Happened

• Pol F. Boudes, a director of Protalix BioTherapeutics, was granted two derivative awards on September 3, 2026: 17,000 and 8,500 shares, for a total of 25,500 shares. Each award is reported at $0.00 per share (award/grant), i.e., restricted stock unit–style compensation rather than an open-market purchase or sale.
• Footnotes indicate these awards are restricted stock units (RSUs) — each RSU represents the right to receive one share of the issuer’s common stock — and they vest in 12 equal quarterly installments commencing on the grant date. This is a compensation award, not an immediate cash investment or sale.

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-04 (timely filing).
• Award amounts/prices: 17,000 RSUs @ $0.00; 8,500 RSUs @ $0.00; total 25,500 RSUs.
• Shares owned after transaction: not stated in the provided filing excerpt.
• Relevant footnotes:
  • RSUs: Each RSU converts to one share after vesting (F3); RSUs vest in 12 equal quarterly installments from grant date (F4).
  • The filing also lists other outstanding option grants NOT part of this award: 40,000 options at $3.55 (exp. 1/20/2030); 50,000 at $1.03 (exp. 9/7/2032); 61,676 at $1.66 (exp. 9/29/2033); 15,000 at $1.64 (exp. 9/3/2035) (F2).
  • A separate footnote describes option vesting schedules (F1) for other option awards.

Context

• RSU grants are common director compensation and vest over time; they do not represent an immediate market purchase or sale. Investors should view this as a compensation-related award rather than an immediate bullish or bearish trade.
• The filing is timely (filed the business day after the grant). No sale, exercise-for-cash, or tax-withholding action was reported in the excerpt provided.